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Cell survival and apoptosis implicate an increasing complexity of players and signaling pathways which regulate not only the
decision-making process of surviving (or dying), but as well the execution of cell death proper. The same complex nature
applies to anoikis, a form of caspase-dependent apoptosis that is largely regulated by integrin-mediated, cell-extracellular matrix
interactions. Not surprisingly, the regulation of cell survival, apoptosis, and anoikis furthermore implicates additional mechanistic
distinctions according to the speciﬁc tissue, cell type, and species. Incidentally, studies in recent years have unearthed yet
another layer of complexity in the regulation of these cell processes, namely, the implication of cell diﬀerentiation state-speciﬁc
mechanisms. Further analyses of such diﬀerentiation state-distinct mechanisms, either under normal or physiopathological
contexts, should increase our understanding of diseases which implicate a deregulation of integrin function, cell survival, and
anoikis.
1.Introduction
A complex assortment of regulatory systems is required for
the embryogenesis and ontogeny, as well as for the main-
tenance, renewal, and repair, of the comprehensive array
of organs and tissues which allow multicellular organisms
like mammals to function and survive. One of such critical
regulatory systems is programmed cell death (PCD) [1–
6], best deﬁned as being “a sequence of events based on
cellular metabolism that lead to cell destruction”[ 1]. Such
a laconic deﬁnition of PCD includes nevertheless three
distinct processes of cell death: apoptosis (caspase-induced
or caspase-independent), autophagic cell death (caspase-
induced or caspase-independent), and programmed necrosis
(caspase-induced or caspase-independent) [1, 2, 7–10]. The
present paper will focus on speciﬁc aspects of the “caspase-
induced apoptosis” side of PCD, particularly with regards to
integrin-mediated signaling.
2.CellSurvivalandApoptosis:
The Ying and Yang of Life and Death
Apoptosis is a ﬁnely tuned process that performs crucial
roles in several embryogenetic and physiological processes,
such as tissue development and homeostasis, as well as the
removal of defective, damaged and/or obsolete cells [1–
10]. It is now well understood that regardless of their state
of being, normal cells are intrinsically wired by default to
enter apoptosis. Consequently, apoptosis must be kept in
a suppressed mode when not needed and, therefore, cells
require survival signals in order to remain alive [1–12].
Depending on the cell type, the said signals will include
those provided by speciﬁc growth factors and their receptors.
Aside from the loss of survival signals, apoptosis can also
be induced by selected proinﬂammatory cytokines, as well
as through various insults such as those caused by free
radicals, radiation, or DNA-damaging agents, among others2 Journal of Signal Transduction
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[1–10]. In typical instances of apoptosis, the death throes
of a dying cell comprise membrane blebbing, chromatin
condensation, DNA degradation, organelle destruction, and
cell shrinkage [1–10]. Ultimately, the process results in the
formation of apoptotic bodies that are either phagocytosed
(by macrophages or neighboring cells), or simply released
into a lumen for subsequent evacuation [1, 2, 4, 7–9, 13].
The Bcl-2 (“B-cell chronic lymphocytic leukemia/lym-
phoma 2”) family of proteins—or homologs—is well known
to constitute a critical decisional center of cell survival and
apoptosis [6, 8, 11, 12, 14–17]. Some twenty members of
this family have been identiﬁed so far in man [11, 12, 14–
17]. While most Bcl-2 homologs are ubiquitously expressed
regardless of the cell type [6, 8, 11, 12, 14–17], some may
be prominently, or even selectively, expressed in a more
restricted subset of tissues [6, 8, 11, 12, 14–17]. Alternately,
some homologs will become expressed following speciﬁc
apoptotic stimuli. A classic example of this is the p53-driven
induction of the expression of the pro-apoptotics Puma and
Noxa following DNA damage, consequently forcing cells to
undergo apoptosis [6, 8, 11, 12, 14–17]. Bcl-2 homologs act
primarily as apoptotic suppressors (“anti-apoptotics”; e.g.,
Bcl-2, Bcl-XL, Mcl-1), eﬀectors (“pro-apoptotics”; namely,
Bax,Bak,andBok),activators(pro-apoptotics;e.g.,Bid/tBid,
Bim, Puma), or sensitizers (pro-apoptotics; e.g., Bad, Bmf,
Bik, Noxa) (Figure 1)[ 6, 8, 11, 12, 14–17]. In general,
the suppressors interact with the eﬀectors in the cytosol
to prevent eﬀector translocation to mitochondria. Alter-
nately, suppressors will bind eﬀectors already present at
mitochondrial membranes in order to prevent them from
oligomerizing (Figure 1)[ 6, 8, 11, 12, 14–17]. Upon a given
apoptotic stimulus, the balance of anti- and pro-apoptotic
homolog expression and activities will be aﬀected so that
the sensitizers and activators gain the upper hand, therefore
allowing both groups to inhibit suppressors (Figure 1)[ 6,
8, 11, 12, 14–17]. Additionally, activators will synergize with
eﬀectorstoeitherhelpthelattertranslocatetomitochondria,
or oligomerize with them at mitochondrial membranes
(Figure 1)[ 6, 8, 11, 12, 14–17]. The end result is that
eﬀectors are now in force at mitochondrial membranes and
are free to homo-oligomerize, or hetero-oligomerize, with
activatorsorothereﬀectors,inordertoformpores(Figure1)Journal of Signal Transduction 3
[6, 8, 11, 12, 14–17]. The consequent loss of mitochondrial
membrane integrity leads to, among many things, the release
of cytochrome c into the cytosol. Cytochrome c acts as
a cofactor with APAF-1 (“Apoptosis Protease Activating
Factor-1”) in recruiting the precursor/inactive form of the
initiator caspase CASP-9, thus forming the apoptosome and
consequently resulting in the activation of CASP-9 (Figure 1)
[6, 11, 12, 14–18]. In turn, CASP-9 initiates an irreversible
activation-ampliﬁcation cascade of executioner caspases,
such as CASP-3 and CASP-7, which will cleave their many
substrates (e.g., actin, kinases, lamins, and keratins). More-
over, executioner caspases will activate by cleavage other
apoptotic executioners such as CAD (“Caspase-Activated
Dnase”), which enacts internucleosomal DNA degradation
(Figure 1)[ 11, 12, 14–17, 19]. Lastly, numerous additional
molecules that are implicated in the decision (or execution)
of apoptosis have been identiﬁed to date, including cytosolic
IAPs (“Inhibitors of Apoptosis”) which can inhibit caspases,
as well as IAP inhibitors (e.g., Smac/Diablo, Omni) which
are released during the loss of mitochondrial membrane
integrity (Figure 1)[ 6, 8, 11, 12, 14–18, 20–23].
Thus, the fate of a cell depends principally on a
tightly modulated balancing act between the anti- and pro-
apoptotic activities from multiple Bcl-2 homologs [6, 8,
11, 12, 14–17]. Such a balance is established at its base
through a modulation of the expression of various homologs
according to the speciﬁc survival stimulus, cell type, and
species concerned. However, post-transcriptional and/or
post-translational modulations (e.g., alternative splicing,
phosphorylation, sequestration) also contribute signiﬁcantly
to this balance [11, 12, 14–17, 24–26]. For instance, the
phosphorylation of Bad on either of the S112, S136, or
S155 residues inactivates its sensitizer functions, whereas
phosphorylationofatleasttwooftheseresiduesfurthermore
leads to its degradation by proteasome. Another example is
the case of Bid, which is normally expressed as an inactive
precursor, and which consequently requires cleavage into
its tBid form in order to enact its activator functions. Also
of note are Bim and Bmf, two homologs that are typi-
cally sequestered in microtubules and actin microﬁlaments,
respectively, therefore requiring their liberation from such
captivity in order to perform their pro-apoptotic functions
[11, 12, 14–17, 24–28].
It is of note that the establishment of the apoptosome
(and consequent CASP-9 activation) constitutes what is
generally recognized as the intrinsic, or “common,” pathway
ofapoptosis.Thismodeistypicallyinducedbypro-apoptotic
stimuli such as the loss of survival signals or critical failures
in the operation of cellular processes (e.g., high-error DNA
replication, plasma membrane peroxidation, DNA damage,
protein misfolding, mitochondrial dysfunction) [1–12, 17,
18]. However, there is another mode of induction of apop-
tosis known as the extrinsic (or “death receptor,” “receptor-
mediated”) pathway. This mode is induced by one type
of pro-apoptotic stimulus, namely, the binding of “death
ligands” (e.g., tumor necrosis factor (TNF)-α, FasL, or TNF-
related apoptosis-inducing ligand/TRAIL) to speciﬁc “death
receptors.”Onceactivated,thesereceptorsleadtotherecruit-
ment of adaptor proteins such as FADD (“Fas-associated
Death Domain protein”), which in turn recruit the precur-
sor/inactive form of the initiator caspase CASP-8 in order
to form the DISC (“Death Inducing Signaling Complex”).
Consequently, this results in the activation of CASP-8 [10–
12, 17, 29–32]. In cells with a high density of death receptors
and/or high expression of pro-CASP-8, the DISC-induced
activation of CASP-8 will be of suﬃcient intensity to bring
about a subsequent amplifying activation cascade of execu-
tioner caspases, therefore rendering the process irreversible.
However,incellswithalowdensityofdeathreceptorsand/or
low expression of pro-CASP-8, the DISC-induced activation
of CASP-8 will be instead of low intensity, in turn leading
to low-intensity executioner caspase activation. In this situ-
ation, CASP-8 (and/or executioner caspases) will then have
to (a) cleave Bid into its activator-functional tBid form, (b)
destabilize actin microﬁlaments and microtubules by cleav-
age to allow the release of Bmf and Bim, and/or (c) cleave
microtubule-sequestered Bim in order to directly release it.
These altogether lead to a subsequent shift in the balance of
anti- and pro-apoptotic Bcl-2 homolog activities, in eﬀect
causing a translocation of the death signal to mitochondria
fortheformationoftheapoptosomeandactivationofCASP-
9—andthusonlythenrenderingtheprocessirreversible[10–
12, 14–17, 29–32]. The relevance of these considerations will
become apparent in the following sections.
3.IntegrinsandCellSurvival:
GraspingDesperately for Dear Life
Similarly to growth factors and their receptors, cell-
extracellular matrix (ECM) interactions play a major role
in regulating the various known cellular processes, including
the maintenance of cell survival [12, 33–38]. The biological
functions attributed to cell-ECM interactions are mediated
primarilybyintegrintypetransmembranereceptors[12,33–
39].Sofar,18αsubunitsand8β subunitshavebeenidentiﬁed
in humans, with α subunits noncovalently associating with
β subunits in order to form 24 distinct heterodimeric (αβ)
receptors with diﬀering ligand speciﬁcities [39–44]. Some α
and β subunits can undergo post-transcriptional alternative
splicing, or post-translational proteolytic processing, result-
ing largely in variants with alterations in their cytoplasmic
tails in order to add further versatility to their roles and
functions [39–43].
Integrins can be divided into three main functional
groups: cell-cell adhesion integrins, vascular integrins, and
cell-ECM adhesion integrins. It is those integrins that have
the β1 subunit in common which constitute the majority of
receptorsforECMcomponents[39–43].Alsoofthisgroupis
the α6β4 integrin, which is expressed exclusively in epithelial
cells [39, 44]. The repertoire of integrins (and variants)
expressed by a given cell is dependent on the contexts of
ECM composition, tissue-type, and species concerned [33–
44]. Taking into account that some ECM components may
be bound by more than one integrin, it is therefore not
surprising that integrin-mediated cellular responses to the
ECM are quite varied and multifaceted [39–44]. To this
eﬀect, the initial observations that a cell’s anchorage to its
ECM constitutes a critical factor for its survival [45, 46]4 Journal of Signal Transduction
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were quickly followed by the realization that distinct ECM
components and integrins are selectively implicated in the
promotion of cell survival, depending on the tissue and
speciesstudied[33–35,39,44,47–49].Forinstance,laminin-
211 promotes the survival of human and mouse skeletal
myocytes via the α7Bβ1D integrin (a laminin receptor),
whereas laminin-511 and ﬁbronectin fail to support myocyte
survival [50–53]. Also in myocytes, laminin-211 upregulates
the expression of Bcl-2 and Bcl-XL, promotes the S112
phosphorylationofBad,anddownregulatestheexpressionof
Bax and Bak, whereas laminin-511 enacts the exact opposite
eﬀects [53]. Additionally, laminin-111 can actually replace
laminin-211 to promote the survival of mouse skeletal
myocytes [54–57], but not human ones [50], and does so at
least in part via the α7Bβ1D integrin [54, 57].
The binding of an integrin to its ECM ligand produces
not only a physical link with the cytoskeleton, but also
generates a vast range of transduction signals which aﬀectJournal of Signal Transduction 5
cell behavior, cell shape, and gene expression [12, 33, 34,
36, 43, 47–49, 58–61]. It is now well established that a
given repertoire of expressed integrins not only engenders
distinct signals for a speciﬁc cell type, but also exerts a
diﬀerential modulation of cellular processes within the same
tissue [33–44, 47, 48, 58–61]. Although well advanced, our
understanding of the exact molecular bases of integrin-
mediated signaling remains incomplete [58–61]. It is nev-
ertheless known that an increasing number of pathways
such as the phosphatidylinositol 3-kinase (PI3-K)/Akt path-
way, the MEK (“Mitogen-Activated Protein Kinase (MAP)
Kinase”)/Erk (“Extracellular Regulated Kinase”) pathway,
or the SAPKs (“Stress-Activated MAP Kinases”) JNK (“c-
Jun N-terminal Kinases”) and p38, can be activated alone
or in combination according to the repertoire of integrins
expressed by a given cell [12, 34, 36, 43, 48, 58–62].
However, unlike most growth factor receptors, integrins
are nonkinase receptors. Consequently, integrins require
kinase proxies to enact signal transduction following their
activation. To this eﬀect, signaling by β1 integrins owes
largely to the recruitment and activation of Fak (“Focal
Adhesion Kinase”) at the cytoplasmic tail of the β1 subunit.
In turn, Fak typically recruits and activates Src [12, 33,
34, 36, 48, 58–73]. Conversely, Src may be the ﬁrst to
be recruited and activated at the cytoplasmic tails of β
subunits [62, 71, 74] and in turn recruit/activate Fak [62,
63, 65, 67, 71]. Such integrin-mediated Fak/Src signaling
allows for the downstream engagement of a plethora of
pathways, largely due to the formation of diverse signal-
ing cassettes through the recruitment by Fak and/or Src
of an increasing array of signaling molecules. These can
include adaptors (e.g., Sch, Grb2), scaﬀolders (e.g., IRS-
1—“Insulin Receptor Substrate-1”), nucleotide exchangers
(e.g., SoS), small GTPases (e.g., Ras), and other kinases (e.g.,
Cas) (Figure 2)[ 62–73, 75]. Similarly, integrin-mediated
Fak/Src signaling contributes greatly in the assembly of focal
adhesions via their interactions with a mounting number
of partners (e.g., paxillin, talin, and vinculin), in order
to not only create a bridge between the ECM and the
actin cytoskeleton, but also to regulate the stability and
organization of actin microﬁlaments [48, 58–65, 69, 71, 75,
76]. This enables, or maintains, the sequestration of Bmf
and/orBim(Figure2).Themodulationofintegrin-mediated
signaling and focal adhesion assembly can also be generated
via certain α subunits (e.g., activation of Src family members
FynorYes),viatheassociationwithmembraneproteins(e.g.,
caveolin), or via other adaptors and kinases, such as ILK
(“Integrin-Linked Kinase”) (Figure 2)[ 34, 39, 43, 48, 58–
62, 76–78]. Incidentally, the epithelial α6β4 integrin likewise
participatesinthestimulationofpathwayssuchasPI3-K/Akt
and/or MEK/Erk via its engagement of Src (but not Fak)
and furthermore is a chief contributor in the formation of
hemidesmosomes—anchoring complexes which link physi-
cally the ECM to keratin intermediate ﬁlaments, thus further
organizing/stabilizing the cytoskeleton of a cell [39, 44, 58,
79, 80].
Overall, signal transduction by integrins diﬀers little
from that of growth factor receptors with tyrosine kinase
activity (“RTKs”). It is therefore not surprising that there is
much chatter between RTK- and integrin-mediated signal-
ing, the two often cooperating in the regulation of various
cell processes such as proliferation, migration, and survival
[12, 33, 34, 39, 43, 44, 58–73, 77, 79–87]. To this eﬀect,
integrins can enact “inside-out” activation of RTK signaling
largely through their own engagement of Fak, Src and/or ILK
[62–73, 77–79, 82–87]. Reciprocity being the rule, RTKs can
perform inside-out activation of integrin signaling, mainly
through their own engagement of Src [64–66, 69–71, 86,
87]. Therefore, the already wide range of integrin-mediated
signals can be expanded vastly further through such cross-
talk with various growth factor receptors.
The precise molecular mechanisms governing the pro-
motion of cell survival by integrins remain to be fully
elucidated. Nonetheless, PI3-K/Akt and Ras/Raf/MEK/Erk
constitute the best known cell survival-promoting pathways
among the assorted ones identiﬁed so far as being engaged
by integrin-mediated Fak/Src signaling [12, 33–36, 47, 58–
66, 68–70, 72, 73, 80, 81, 88–101]. With regards to the PI3-
K/Akt pathway, Akt is well known for its numerous cell
survival functions such as the inhibitory phosphorylation
of Bax (on the S184 residue), Bad (on S136 preferentially,
but on S112 as well), and Bim (on S87), as well as the
phosphorylation of pro-CASP-9 (on S196) to suppress its
activation and the inhibitory phosphorylation of GSK-3β
(“Glycogen Synthase Kinase-3β”; on S9) which, when active,
positively phosphorylates Bax (on S163) and negatively
phosphorylates Mcl-1 (on S155, S159 and T163) (Figure 2)
[11, 12, 14–17, 24–26, 34, 81, 88–94, 101]. Although ILK
contributes in the formation of integrin-mediated focal
adhesions by binding directly to the cytoplasmic tail of the
β s u b u n i t so fa c t i v a t e dr e c e p t o r s[ 76–78], it has also been
shown to be PI3-K-dependent for its activation and capable
of acting as an upstream contributor to the activation of Akt
[82–84, 88, 89, 91]. However, with the recent evidence that
ILK is a pseudokinase [102, 103], its previously tacit kinase
activation upon binding the cytoplasmic domain of integrin
β subunits, as well as its kinase signaling roles in promoting
integrin-mediatedcellsurvival,remainthereforecontentious
[82–84, 102, 103]. At the very least, the scaﬀolding functions
of ILK in focal adhesion assembly and actin microﬁlament
linkage [76–78], as well as its implication in microtubule
assembly [104], are likely to contribute in the sequestration
of Bmf and Bim (Figure 2). Similarly, the said scaﬀolding
functions of ILK can be used by integrins to cross-talk with
RTKs, thus allowing for its contribution in RTK/integrin
cooperative signaling in promoting cell survival [77, 78, 82–
86].
Regarding the Ras/Raf/MEK/Erk pathway, Raf can phos-
phorylate Bcl-2 (on T69/S70) in order to potentialize
its suppressor functions, whereas RSK-1 (“p90 Ribosomal
S6 Kinase-1”), a usual eﬀector of Erk1/Erk2, enacts an
inhibitory phosphorylation of Bad (on S112) (Figure 2)[ 11,
12, 14–17, 24–26, 81, 95–99, 101, 105–107]. Additionally,
Erk1/Erk2 themselves may phosphorylate Bcl-2 (presumably
on T69/S70) to potentialize its suppressor functions, Mcl-1
(presumably on S159/T163) to protect it from degradation,
Bim(onS69and/orS87)toinhibititsactivatorfunctionsand
pro-CASP-9 (on T125) to prevent its activation (Figure 2)6 Journal of Signal Transduction
[11, 12, 14–17, 24–26, 81, 95–99, 101, 105, 106]. The
PI3-K/Akt and Ras/Raf/MEK/Erk pathways can furthermore
cross-talk with each other in order to cooperatively promote
cell survival. For instance, Ras can activate PI3-K, which
in turn results in the activation of Akt. Moreover, PDK1
(“Phosphoinositide-Dependent Kinase-1”), another eﬀector
of PI3-K, can activate RSK-1 [88, 94, 106, 107]. In any event,
the engagement of PI3-K/Akt and/or Ras/Raf/MEK/Erk
results generally in an up-regulation of the expression
of anti-apoptotic Bcl-2 homologs and IAPs, as well as a
down-regulation of the expression of pro-apoptotic Bcl-2
homologs (Figure 2)[ 11, 12, 14–17, 21, 22, 60, 81, 88–99].
Additionally, the expression of c-Flip (“cellular FADD-like
IL-1β-converting enzyme-inhibitory protein”), which blocks
the formation of the DISC by binding to FADD [12, 30, 32,
81], is likewise up-regulated [12, 60, 81, 88–99].
Hence, the importance of Fak and/or Src in the integrin-
mediated promotion of cell survival is intimately linked with
their pivotal role in the engagement of pathways such as
PI3-K/Akt and/or Ras/Raf/MEK/Erk (Figure 2), depending
on the composition of the signaling cassettes they help
engender and the speciﬁc integrin receptors implicated, as
well as according to the cell type and species studied [12,
34, 43, 47, 48, 58–73, 80]. Interestingly, Fak and Src can also
contribute directly in the promotion of cell survival, aside
from their usual roles in the integrin-mediated assembly
of focal adhesions and engagement of survival-promoting
pathways (Figure 2). Indeed, Src can phosphorylate pro-
CASP-8 (on Y380) to suppress its activation [108], whereas
Fak can bind RIP1 (“Receptor-Interacting Protein-1”; a.k.a.
RIPK1) in order to prevent its recruitment of FADD and
consequent formation of the DISC [109, 110]. All in all, it is
therefore more than ever undisputable that a cell’s integrin-
mediated anchorage to its ECM constitutes a powerful,
multilayered, and complex device whose most signiﬁcant
purpose is to ensure survival. It should be noted here
that the already complicated nature of the regulation of
cell processes is strikingly enhanced by the implication
of speciﬁc kinase isoforms and/or family kinase members,
thereforeoftenresultingindistinct—orevendiﬀering—roles
by the pathways in which they participate. PI3-K isoforms
complexes(4catalyticsubunitisoforms,3regulatorysubunit
isoforms), Akt isoforms (−1t o−3), RSK isoforms (−1t o
−4), IRS isoforms (−1t o−4), or Shc (p46Shc,p 5 2 Shc,p 6 6 Shc)
and Raf (A- to C-) family members, constitute but a few
examples identiﬁed to date in humans [71, 94–96, 98, 101,
105–107, 111–113]. That these can be selectively expressed
depending on the tissue and species, in addition to the fact
thattheycanperformspeciﬁcfunctionsevenwithinthesame
given cell type, further emphasizes the reality of the vast
intricacies that underlie the regulation of cell processes—
including of course cell survival, whether integrin mediated
or otherwise.
4. Integrinsand Anoikis:Making SureThat
LettingGoReally Meansthe End
Considering the importance of integrin-mediated cell-ECM
interactions in driving cell survival, it is therefore not
surprising that the disruption, or loss, of integrin bind-
ing induces PCD—namely, a form of caspase-dependent
apoptosis that is termed anoikis (a.k.a. “detachment-induced
apoptosis” or “integrin-mediated death”) [10, 12, 33–36,
46, 47, 49, 60, 81, 101, 108, 114–120]. Like apoptosis and
PCD in general, anoikis performs important roles during
organogenesis, as well as in tissue maintenance and renewal
[33–35, 38, 49, 79–81, 101, 117–122]. For example, the invo-
lution of mammary glands and the renewal of the epidermis,
as well as that of the intestinal epithelium, implicate the
induction of anoikis in obsolete cells [101, 121–126]. In this
respect, it is now recognized that cells are endowed with
an innate/default anchorage-dependent surveillance system
meant to ensure that all integrins expressed by them do
interact with their respective ECM ligands, thus inducing
anoikiswhenthatisnotthecase.Inotherwords,anycellthat
strays accidentally or otherwise from its assigned position
within its given tissue, either by interacting with a “wrong”
ECM or by losing anchorage to its own ECM, is targeted for
death [12, 36, 60, 108, 115, 117].
Anoikis constitutes overall a “four-punch hit” against
cell survival that implicates elements from both the intrinsic
and extrinsic pathways of caspase-dependent apoptosis. The
ﬁrst “punch” comes from the deactivation of Fak and/or Src,
leading to a disengagement of pathways such as PI3-K/Akt
and Ras/Raf/Mek/Erk (Figure 3). Hence, the numerous
pro-survival roles performed by these pathways (Figure 2)
undergo failure. The second “punch” comes from the con-
comitant disassembly of anchoring focal adhesions (and/or
hemidesmosomes), in large part by the loss of integrin-
mediated engagement of Fak, Src, and/or ILK (Figure 2),
thus greatly destabilizing the cytoskeleton and consequently
allowing the release of Bmf and Bim (Figure 3). Additionally,
the presence of p66Shc (a member of the Shc family of
adaptor proteins [113]) at focal adhesions can induce an
elevated/sustained activation of the small GTPase RhoA,
which in turn contributes likewise in the destabilization of
the cytoskeleton through eﬀectors that remain to be fully
identiﬁed [127]. Interestingly, such “anoikis-sensitizing”
function of p66Shc appears to be independent of its better
known ability to translocate to mitochondria that is typically
part of its apoptosis-inducing roles [113, 127].
The third “punch” consists in the activation of “apop-
totic” kinases [12, 36, 81, 101, 108, 115, 117–120, 128]. The
roles of the SAPKs JNK and p38 in anoikis remain somewhat
ambiguous [95, 96, 98, 101, 117, 129–134]. Three isoforms
for JNK (−1t o−3) and four for p38 (α, β, γ,a n dδ)
have been identiﬁed to date, all of which can be selectively
expressed depending on the cell type and species studied [95,
96, 98, 129–134]. Accordingly, JNK and p38 will contribute
to cell survival or apoptosis/anoikis, or neither, according to
cell type as well as in an isoform-selective manner [95, 96,
98, 129–134]. In addition, and again depending on the cell
context as well as the speciﬁc stimulus, it will be either a
JNK isoform, a p38 isoform, or an isoform of each, which
will be implicated in cell survival or apoptosis/anoikis [95,
96, 98, 101, 129–136]. As example, JNK1 drives anoikis in
canine kidney epithelial cells [128, 137, 138], but not JNK2
[128, 139]. Similarly, p38α is required for apoptosis/anoikisJournal of Signal Transduction 7
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MEKK1∗, constitutive active MEKK1 following caspase-cleavage; scissors: caspase-mediated cleavage.
in rat cardiomyocytes [140] and mouse skeletal myocytes
[52], whereas p38β contributes in the promotion of survival
in the former [140], while playing no role to this eﬀect in the
latter [52]. Consequently, much remains to be understood of
the implication of JNK and/or p38 in anoikis. It is however
generally accepted that a prolonged/sustained activation of
speciﬁc JNK and/or p38 isoforms can allow them more
than enough time to enact their deadlier functions, therefore
driving the cell death process [95, 96, 98, 101, 115, 118, 128–
136]. To this eﬀect, it is now well established that an elevated
and/or sustained activation of an apoptotic JNK isoform, or
p38 one, will result largely from the upstream activation of
ASK-1 (“Apoptosis Signal-regulating Kinase-1”) (Figure 3)
[95, 96, 98, 101, 115, 118, 129–136, 141, 142]. Incidentally,8 Journal of Signal Transduction
Akt phosphorylates ASK-1 (on S83) as part of its pro-
survival functions, thus keeping the latter’s activation in
check (Figures 2-3)[ 88–93, 141, 142]. Little is known of
the precise apoptotic roles, if any, that are enacted by
each speciﬁc JNK and p38 isoforms [95, 96, 98, 129–136].
Nevertheless, it is recognized that apoptosis-induced JNK
or p38 can generally perform numerous apoptotic-driving
functions such as inducing/up-regulating the expression of
FasL (death ligand of Fas) for autocrine “death stimu-
lation,” contributing in the destabilization of cytoskeletal
elements (such as microtubules and microﬁlaments) to
induce/enhance the liberation of Bim and Bmf, contributing
to the membrane blebbing that is characteristic of apoptosis,
down-regulating the expression of IAPs and anti-apoptotic
Bcl-2 homologs while up-regulating that of pro-apoptotic
ones, and phosphorylating homologs either in the cytosol or
at mitochondria (Figure 3)[ 12, 36, 81, 95, 96, 98, 101, 108,
114, 115, 117–120, 129–136]. Apoptotic phosphorylating
functions have been mostly characterized so far in the case
of JNK (albeit not for any particular isoform), namely, the
negative phosphorylation of Bcl-2 (on T69/S70/S87), Bcl-
XL (on S62 and/or T47/T115), and Mcl-1 (on S121/T163),
the phosphorylation of Bax (T167) for its activation and
mitochondrial translocation, the positive/potentiating phos-
phorylation of Bad (S128), the phosphorylation of Bid to
produce an active jBid form (instead of the usual tBid
one), the phosphorylation of Bim (on T56 and either S44
or S58) to prevent its sequestration or cause its release
from microtubules, and the phosphorylation of Bmf (S58
or S77) to prevent its sequestration, or cause its release
from microﬁlaments (Figure 3)[ 11, 12, 14–17, 24–28, 128–
136, 141, 142]. Although similar apoptotic phosphorylations
of Bcl-2 homologs have been reported for p38, the speciﬁc
residues targeted are yet to be ﬁrmly identiﬁed (Figure 3)
[11, 12, 14–17, 24–28, 129–136, 141, 142].
Another apoptotic kinase family of note is the DAPK
family (“Death Associated Protein Kinase”; especially
DAPK1) [143–146]. Although the exact mode of activation
for DAPK1 remains poorly understood, it has been observed
that death receptor signaling (namely, the receptors for
TNF-α and FasL) can lead to DAPK1 activation [143–
148]. Incidentally, Src, Akt, and RSK-1 may phosphory-
late DAPK1 (on Y491/Y492, S308, and S289, resp.) to
maintain it in a repressed, inactive state (Figure 2)[ 143–
148]. Accordingly, the activation of integrins and Fak
results in the suppression of DAPK1 activation [149]. The
apoptotic functions of DAPK1 likewise remain to be fully
elucidated. It is however known that activated DAPK1
contributes greatly to the destabilization of the cytoskeleton
and is critical for membrane blebbing (Figure 3)[ 143–
146]. DAPK1 may furthermore deactivate integrins through
an inside-out mechanism that involves the displacement
and replacement of talin at the cytoplasmic tail of β
subunits, consequently resulting in disassembly of focal
adhesions (Figure 3)[ 149–151]. Interestingly, DAPK1 phos-
phorylates Beclin-1, an autophagic cell death-driving factor
[1–3, 7–9], in order to free it from inhibitory binding
by Bcl-2 and Bcl-XL [145, 146]. Considering that experi-
mental attempts at inhibiting intrinsic pathway apoptotic
eﬀectors following the induction of anoikis often fail to
protect cells, resulting instead in their Beclin-1-mediated
autophagic death [2, 7–10, 118–120], the detachment-
induced activation of DAPK1 is therefore likely to constitute
a functional bridge between anoikis and autophagic cell
death.
The fourth “punch” delivered against cell survival by
the loss of integrin binding consists in the induction of the
extrinsic pathway of apoptosis—that is, CASP-8 activation
(Figure 3)[ 12, 36, 81, 101, 108, 115, 117–120]. Although the
activation of CASP-8 constitutes an early/immediate event
following the loss of integrin-mediated cell adhesion, the
precise mechanisms that are responsible for such activation
remain poorly understood. A part of the puzzle lies with
previous observations that both pro-CASP-8 and activated
CASP-8areassociatedwiththecytoplasmictailsofβ1and/or
β3 subunits of unligated integrins [152, 153]. Interestingly,
pro-CASP-8 is found already associated with the cytoplasmic
tails of integrin β subunits under healthy/adhering condi-
tions [108, 153], most likely due to the fact that pro-CASP-
8 often complexes with Src following its inhibitory phos-
phorylation by the latter [108]. Nonetheless, the formation
of a DISC at unligated integrins as the causal agent for
CASP-8 activationremains contentious, despite reports from
diﬀerent cell types that CASP-8 activation can be FADD-
dependent in anoikis [109, 110, 154–160] and that c-Flip
can inhibit the process [156, 160, 161]. Indeed, with Fak
and Src being downactivated following detachment from
the ECM, RIP1 is freed from Fak [109, 110], and pro-
CASP-8 is no more negatively phosphorylated by Src (see
previous section) [108, 162]. Additionally, the concomitant
downactivation of the PI3-K/Akt and/or Ras/Raf/MEK/Erk
pathwaysleadstoadown-regulationofc-Flipexpression(see
previous section and Figure 3)[ 12, 60, 81, 116–118, 120].
Thus, RIP1, FADD and pro-CASP-8 can complex to form
the DISC [109]. However, it turns out that Fak-freed RIP1
forms a FADD-dependent DISC at the cytoplasmic domain
of the death receptor Fas [110]. In hindsight, that is to
be expected given that, in some cell types, the expression
of FasL can be upregulated following the loss of integrin
binding, or that anoikis can be attenuated/blocked by the
inhibition of Fas [12, 81, 109, 110, 115, 116, 118–120, 154,
155, 160, 161]. Yet in the end, RIP1 does not form a DISC at
unligated integrins [110]. Furthermore, it has been shown
that FADD is not found associated with the cytoplasmic
tails of β3 subunit-containing unligated integrins in human
umbilical vein endothelial cells undergoing anoikis, despite
the fact that pro-CASP-8 and activated CASP-8 are [152].
Most perplexing is what has been reported recently in
human keratinocytes. In these cells, bound β1 integrins
contain the β1A subunit variant, whereas the β1B variant
is expressed in the cytosol and apparently not part of any
functional heterodimeric receptor [153]. As can now be
expected (see above), pro-CASP-8 is found associated with
the cytoplasmic tails of β1A subunits when those cells are
adhering [153]. Upon loss of ECM binding, β1A integrins
are internalized so as to colocalize with the cytosolic β1B
subunits, whereby pro-CASP-8 somehow shuttles from the
tails of the former to those of the latter in order to undergoJournal of Signal Transduction 9
activation in a FADD-independent manner [153]. Hence,
how exactly pro-CASP-8 and/or activated CASP-8 associate
with β subunits of unligated integrins, as well as the precise
mechanisms responsible for CASP-8 activation at these sites,
remain open questions. Although it is not yet established
whether DAPK1 can contribute to the formation of a DISC
[143–148], the fact that activated DAPK1 binds to the
cytoplasmic tail of β subunits of integrins it has deactivated
[149–151] deﬁnitively raises suspicions to that eﬀect, espe-
cially in light of the previous observations in keratinocytes.
Then again, it may simply be that the mechanisms of
CASP-8 activation following the induction of anoikis diﬀer
according to the combined contexts of the cell type, of the
integrin repertoire expressed (including variants), and of the
species concerned—not unlike everything else that has been
discussed herein so far.
In any case, the activation of CASP-8 following the
loss of integrin binding is typically of low-intensity. As a
result, this leads to a likewise low intensity activation of
executioner caspases (Section 2). Hence, anoikis implicates
thenecessaryfollowingevents:(a)caspase-mediatedcleavage
ofBidintoitsactivetBidform;(b)caspase-mediatedcleavage
of pro-survival kinases (e.g., Fak, Akt) for deactivation; (c)
caspase-mediated liberation of Bmf and Bim (Figure 3)
[12, 36, 81, 101, 108, 115, 117–120]. Moreover, MEKK1
(“Mitogen-activated protein kinase kinase kinase 1”), an
upstream activator of the JNK pathway, may be cleaved by
executionercaspases(namely,CASP-7)inordertogeneratea
constitutiveactiveformwhichisresponsibleforaconsequent
prolonged/sustained activation of JNK (JNK1 presumably,
[128, 137, 138]), who then undertakes apoptotic phospho-
rylating functions (see above and Figure 3). Consequently,
these events altogether eﬀect a translocation of the death
signal to mitochondria for the formation of the apoptosome
and activation of CASP-9 (Figure 3). Interestingly, anoikis in
normal cells is characterized by a delay in the irreversible
commitment to the process following the triggering of its
initial pro-apoptotic events [12, 46, 79, 81, 101, 114, 120,
128]. This explains why cells can be rescued from anoikis
by reattachment within a limited time-span subsequent to
their loss of anchorage [12, 46, 79, 81, 101, 114, 120, 128].
Such a “window of anoikis reversibility” varies in length
depending on the cell type and species, thus ranging from
some ﬁfteen minutes to four hours [12, 46, 79, 81, 101,
114, 120, 128]. It is thought that a window of anoikis
reversibility depends primarily on the time-span required
for the death signal to reach mitochondria, according to the
speciﬁcintegrins(andvariants)implicated,theprecisedeter-
minants of cell survival/death in play (e.g., Bcl-2 homolog
expression proﬁles, survival pathways/isoforms engaged,
apoptotic kinases/isoforms involved, etc.), and the degree
of cytoskeletal organization/cell polarity imparted not only
by integrins (i.e., focal adhesions, hemidesmosomes), but as
well by cell-cell interactions (e.g., E-cadherins). Indeed, the
latter sensitize cells to anoikis by further linking/organizing
the cytoskeleton, albeit contributing at the same time to
cell survival signaling [12, 46, 81, 114, 115, 128, 163, 164].
Additionally, it has been observed that the activation of
pro-survival kinases such as Src, Akt and/or Erk1/Erk2
undergoesashort(ﬁvetoﬁfteenminutesinlength),transient
up-activation following the loss of anchorage. While the
mechanisms responsible for these “deathly gasps” remain
unclear,theyareﬁrstandforemostconsideredtoactasapro-
tection against transient detachments from the ECM, such as
those required during normal cell processes like migration
or cytokinesis. Accordingly, these may also contribute in
deﬁningawindowofanoikisreversibility[12,46,79,81,114,
120]. However, considering the recent evidence that an up-
activationofMEK/Erkinnormalcellscanactuallytriggerthe
intrinsic apoptotic pathway [165, 166], or activate DAPK1
and a consequent autophagic cell death [148, 149, 165, 166],
the question arises whether such “deathly gasps” may not
in fact represent “poisoned fruits.” Be that as it may, it
is clear that once CASP-9 activation occurs, any window
of reversibility is shut and anoikis becomes irreversible—
so much so, in fact, that attempts from this point on to
inhibit the process result in Beclin-1-driven autophagic cell
death (see above) [2, 7–10, 118–120]. To this eﬀect, this may
explain why the overexpression of Bcl-2 or Bcl-XL alone can
protect cells from anoikis [12, 36, 53, 81, 114, 117–120, 128,
137, 167], as such overexpression would not only manage to
block the translocation of the death signal to mitochondria
followingdetachment,butfurthermorepreventthetriggerof
autophagiccelldeathbyanoverwhelminginhibitorybinding
to Beclin-1.
Given that normal cells require a sound anchorage to
their ECM in order to live, and in view of the “four-
punch hit” described above that occurs following the loss
of integrin-mediated attachment, it is therefore usually
considered that integrins suppress anoikis [12, 81, 101, 120–
123]. This is well exempliﬁed by the observations that
the forced expression of dominant negative mutants of
Fak and/or Src readily induces anoikis, whereas the forced
expression of constitutive active mutants of either, or both,
protects against it [12, 60, 63–73, 81, 99–101, 114, 119, 120,
168]. Likewise, similar results are obtained when mutants
of kinases that are engaged by integrin/Fak/Src-mediated
cell survival signaling are used, such as PI3-K or Akt [12,
60, 63–73, 81, 81, 88–99, 99, 100, 100, 101, 101, 114, 119,
120]. However, there is now evidence that some integrins
may actually sensitize cells to anoikis. As example, the
knockdown of the expression of α8β1 in human intestinal
epithelial crypt cells results in the loss of vinculin at focal
adhesions and confers a measure of anoikis resistance via
an illicitly sustained activation of Fak [169]. Although it
remains unclear by which mechanisms Fak activation is
thus sustained, it is germane that vinculin has been shown
to enforce the adhesion-dependent activation/deactivation
of Fak [60, 67, 170, 171] and that the gene disruption of
vinculin in F9 mouse embryonic carcinoma cells renders
them resistant to anoikis, also via a sustained activation of
Fak [170]. Another example of anoikis-sensitizing integrin
is αvβ3 in colon cancer cells, although it is not known how
this integrin enacts such a sensitizing function [172, 173].
It is thought that anoikis-sensitizing integrins may be part
of the above-mentioned anchorage-dependent surveillance
system,asameanstofurtherwarrantthedisposalofcellsthat
detachfromtheirECM[169].However,itisalreadyclearthat10 Journal of Signal Transduction
anoikis-sensitizing functions will be undertaken by speciﬁc
integrins according to the cell type. Indeed, αvβ3i sb e t t e r
known for its anoikis-suppressing roles in endothelial cells,
among other cell types [174, 175], whereas α8β1 has already
been reported to suppress anoikis in myoﬁbroblasts [176].
Overall, the preceding considerations altogether demon-
strate the multilayered complexities that underlie the reg-
ulation of cell survival, apoptosis, and anoikis. Moreover,
these include further mechanistic distinctions according to
the contexts of the composition of the ECM, the speciﬁc
integrins implicated, the cell type, and the species. However,
studies in recent years in one tissue in particular, the human
intestinal epithelium, have unearthed yet another level of
intricacy in the regulation of these processes, namely, the
implication of distinct mechanisms according to the state of
cell diﬀerentiation.
5. Differentiation State-SpeciﬁcRegulation of
CellSurvival,Anoikis:Difference Is the Key
The intestinal epithelium is an elegant and valuable physio-
logical system for understanding the functional connections
between integrin-mediated cell-ECM interactions and the
cell state [101, 125, 177–181]. The continuous renewal of
this simple columnar epithelium occurs along a well-deﬁned
unit, the crypt-villus axis. This unit consists generally in
two cell populations: the proliferative, immature cells of
the crypt and the diﬀerentiated cells of the villus [125,
126]. As part of the dynamic process of intestinal epithelial
renewal, obsolete enterocytes enter anoikis upon reaching
the apex of the villi, as a means of exfoliation [101,
125, 126, 180]. For their part, crypt cells can occasionally
u n d e r g oa p o p t o s i si no r d e rt oe v a c u a t ed a u g h t e rc e l l s
that are damaged or defective [101, 125, 126, 180]. Such
apparent contrast of destiny between undiﬀerentiated and
diﬀerentiatedenterocytesalongthecrypt-villusaxis,coupled
with their speciﬁc proﬁles of expression of Bcl-2 homologs
whichareestablishedduringthediﬀerentiationprocess[101,
125, 182–186], initially introduced the concept of a distinct
modulation of cell survival and apoptosis according to the
state of diﬀerentiation [101, 125, 184]. This concept so far
has been demonstrated mostly in human intestinal epithelial
cells [101, 125]. For instance, the individual expression of
Bcl-2 homologs is subjected to speciﬁc regulatory mecha-
nisms depending on the diﬀerentiation status of enterocytes
[167, 185–187]. As example, the PI3-K/Akt-1 and MEK/Erk
pathways are selectively implicated in the promotion of
enterocytic survival according to the state of diﬀerentiation,
including with regards to their modulation of the expres-
sion/activity of Bcl-2 homologs (Figure 4)[ 167, 185–187]. In
thisrespect,PI3-K/Akt-1,butnotMEK/Erk,iscriticalforthe
survival of undiﬀerentiated/crypt enterocytes, whereas both
pathwaysarevitalforthesurvivalofdiﬀerentiated/villusones
(Figure 4)[ 167, 185–187].
Theobviousfollow-upquestioniswhethertheconceptof
adistinctmodulationofcellsurvivalandapoptosisaccording
to the state of diﬀerentiation applies as well to integrin-
mediatedcellsurvivalandanoikis.Ineﬀect,humanintestinal
epithelial crypt and villus cells express diﬀerential proﬁles of
integrins as they interact with speciﬁc basement membrane
components, which are likewise deposited diﬀerentially
along the crypt-villus axis [125, 177–181, 184, 188]. As
expected when considering the normal fate of villus cells (see
a b o v e ) ,i tt u r n so u tt h a td i ﬀerentiated/villus enterocytes are
more susceptible to anoikis than their undiﬀerentiated/crypt
counterparts [185, 189, 190]. Although crypt cells express
the α8β1 receptor as an anoikis-sensitizing integrin [169],
the villus cells are nonetheless highly polarized in addition
to bearing E-cadherin adherens junctions, in stark contrast
to the former [163]. Moreover, such distinctions in anoikis
susceptibility between crypt and villus enterocytes translate
into diﬀerentiation state-speciﬁc mechanisms of integrin-
mediated cell survival and anoikis (Figure 4)[ 167, 185, 186,
189–191]. For instance, β1 integrins, Fak, and Src distinc-
tively modulate the expression/activity of Bcl-2 homologs
dependingontheenterocyticdiﬀerentiationstatus(Figure4)
[167, 185, 186, 190]. Furthermore, α2β1, α5β1, and α6Aβ1
are required for the survival of undiﬀerentiated enterocytes,
whereas α3β1, α6Bβ1a n dα6Bβ4A are required for the
survival of diﬀerentiated ones [185, 186] (S. Thibodeau
and P.H. Vachon, manuscript in preparation). Similarly,
the engagement of PI3-K/Akt-1 is integrin β1/Fak/Src-
dependent in undiﬀerentiated cells, but Src-independent in
diﬀerentiated ones, whereas the engagement of MEK/Erk
remains integrin β1/Fak/Src-dependent regardless of the
state of diﬀerentiation (Figure 4)[ 167, 185, 186, 189–191].
To this eﬀect, the integrin β1/Fak/Src/PI3-K/Akt-1 pathway
antagonizes the apoptotic activation of p38β in undiﬀeren-
tiated enterocytes, whereas the integrin β1/Fak/PI3-K/Akt-1
and integrin β1/Fak/Src/MEK/Erk pathways both contribute
inantagonizingthatofp38δ,indiﬀerentiatedones(Figure4)
[167, 186, 189].
Consequently, the regulation of integrin-mediated cell
survival and anoikis is indeed subjected to diﬀerentiation-
state-speciﬁc mechanisms (Figure 4). However, the overall
concept of diﬀerentiation state-speciﬁc controls of cell sur-
vival, apoptosis, and anoikis does not constitute a peculiarity
of the intestinal epithelium, since it evidently applies to
othertissues—albeitnotwithoutobligatorycelltype-and/or
species-dependent distinctions. For instance, skeletal muscle
myoblasts require ﬁbronectin and α5β1 Ai no r d e rt os u rv i v e ,
whereas myocytes require instead laminin-211 and α7Bβ1D
[50–53]. Furthermore, myoblasts depend on an integrin-
driven Fak/Src/MEK/Erk pathway for their survival, whereas
myocytes depend instead on an integrin-driven Fyn/PI3-
K/Akt-2 one [52, 53, 192, 193]. A fundamental challenge
now presenting itself lies in the search for answers to
three broad questions regarding such diﬀerentiation state-
speciﬁc mechanisms of cell survival, apoptosis and anoikis,
namely: (a) the “why” for the existence of such distinct
mechanisms according to the state of cell diﬀerentiation; (b)
the “how” of these distinct mechanisms (i.e., the further
functional identiﬁcation of speciﬁc extracellular ligands,
integrins and molecules/pathways involved, as well as their
respective diﬀerentiation-speciﬁc roles in the suppression or
induction of apoptosis/anoikis); (c) the “in what capacity”
thesesamediﬀerentiation-speciﬁcmechanismscontributein
the emergence of diseases when they become deregulated.Journal of Signal Transduction 11
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Figure 4: Diﬀerentiation state-speciﬁc mechanisms of integrin β1/Fak/Src-mediated control of human intestinal epithelial cell survival and
anoikis. In undiﬀerentiated enterocytes (a), β1 integrin/Fak signaling recruits Src which acts as a cornerstone in the subsequent engagement
of PI3-K/Akt-1 and MEK/Erk in the suppression of anoikis. However, in contrast to PI3-K/Akt-1, MEK/Erk is not required for survival
due to its non-to-marginal roles in the regulation of the expression/functions of Bcl-2 homologs and its noninvolvement in suppressing
the activation of the enterocyte undiﬀerentiated state-selective apoptotic kinase isoform p38β.I nd i ﬀerentiated enterocytes (b), MEK/Erk
remains Src dependent but not PI3-K/Akt-1(which however remains Fak-dependent). PI3-K/Akt-1and MEK/Erk are now both required for
survival, as they both play major roles in the regulation of Bcl-2 homolog expression/functions as well as in suppressing the activation of the
enterocyte diﬀerentiated state-selective apoptotic kinase isoform p38δ. +, up-regulation of expression; −, down-regulation of expression.12 Journal of Signal Transduction
6. Integrins,Anoikis,and Disease:
Too MuchorNotEnough,It’sStillUnhealthy
As in the case of apoptosis, there is an increasing num-
ber of pathological disorders that are characterized by a
deregulation of integrin-mediated cell survival, and anoikis
signaling [35, 39, 44, 49, 117, 118, 120, 194]. Certain
forms of muscular dystrophy and epidermolysis bullosa
constitute classic examples of pathologies that are caused
primarily by a deregulated induction of anoikis [39, 44,
79, 80, 195–197]. Accordingly, the need to understand
the regulation of cell survival and apoptosis has gained
much importance in cancer research, especially since the
acquisition of a resistance to anoikis constitutes a critical
step in tumor progression—particularly in the emergence
of invasive and metastatic cells [86, 116, 118–120, 174,
188, 198–200]. Incidentally, cancer cells are notorious for
exhibiting major alterations in their repertoire of expressed
integrins [49, 62, 80, 86, 174, 180, 188, 199, 200], as
well as in their surrounding ECM [35, 49, 180, 188, 200].
Moreover, metastatic cells are infamous for displaying a
marked resistance to anoikis [86, 116, 118–120, 174, 188,
198–200]. To this eﬀect, much attention has been given to
Fak and Src in tumor progression [63–73, 201], as well as
to downstream pathways engaged by them, such as PI3-
K/Akt and MEK/Erk [88–99]. Along with these, virtually
every known player in the intrinsic and extrinsic pathways
of apoptosis is likewise being scrutinized, in order to not
only seek an eventual understanding of the acquisition of
resistance to anoikis (and/or apoptosis) by cancer cells, but
as well as to identify molecular targets that are susceptible
to shut down such problematic resistance. Thus, anoikis-
sensitizing integrins may be added to this expanding list, in
view of the observations that anoikis-resistant colon cancer
cells do not express α8β1, whereas forcing its expression
reinstates in them a good measure of susceptibility to
anoikis [169]. Similarly, colon cancer cells that are anoikis-
sensitive acquire a resistance to the process following their
loss of expression of αvβ3[ 172]. However, the cross-talk
between integrins and RTKs further complicates matters
greatly, since the deregulated activity of an RTK can confer
resistance to anoikis by maintaining/enhancing integrin-
mediated cell survival after the loss of attachment, via
inside-out signaling [12, 34, 86, 87, 116, 117, 119, 120,
174, 175]. As one example among many, colon cancer
cells that strongly express EGF/TGF-α (“Epidermal Growth
Factor/Transforming Growth Factor-α”) display a resistance
to anoikis by at least in part sustaining the activation of
Src via autocrine stimulation of EGFR (“EGF Receptor”),
therefore allowing Src to maintain functional interactions
with Fak and consequently sustaining a Fak/Src-mediated
suppression of anoikis [202]. In this respect, the deregula-
tion of RTK signaling is well known to induce epithelial-
mesenchymal transition (EMT) in normal epithelial cells, a
phenotypic change that is considered a prerequisite for the
acquisition of anchorage-independent growth and resistance
to anoikis, consequently leading to the emergence of invasive
and metastatic cancer cells [62, 66–73, 85–87, 116, 119, 120,
200, 201, 203].
Hence, the task of elucidating the mechanisms of
resistance to anoikis in cancer cells, let alone identifying
commonalities, is evidently proving to be a daunting one—
and that is without taking into account the inherent
molecular diﬀerences between the various types of cancers,
as well as the cellular and molecular heterogeneity that
is invariably found within any given cancer. Nevertheless,
increasing our knowledge of those determinants which
control cell survival, apoptosis, and anoikis within a speciﬁc
tissue will, in turn, add further to our comprehension of
apoptosis/anoikis-linked diseases of said tissue, in addition
to paving the way toward the design of targeted molecular
therapeutic approaches that are both tissue- and disease-
selective. To this end, the inclusion of acquiring a better
g r a s po fd i ﬀerentiation state-speciﬁc distinctions in the
integrin-mediated regulation of cell survival and anoikis
in such research endeavors would not only allow for a
more complete understanding of a given tissue’s normal
physiology, but furthermore provide a full accounting of the
physiopathological underpinnings of its apoptosis/anoikis-
linked diseases—including tumorigenesis and tumorigenic
progression. Incidentally, cancerous intestinal epithelial cells
display integrin/Fak/Src anoikis-suppressing signaling fea-
tures that are similar to either their normal undiﬀerentiated
or diﬀerentiated counterparts, and do so regardless of their
own degree of cell dediﬀerentiation [202] .W h e t h e ro rn o t
cancer cells of other tissues do likewise remains, however, to
be conﬁrmed.
7. Post-Mortem and Conclusions
Cells requiresurvivalsignals inordertolive,andinteractions
with their ECM through integrins constitute a critical
contributor to this eﬀect. Integrin-mediated cell survival
and anoikis comprise a multifaceted and multilayered
surveillance mechanism which is responsible for upholding
the correct position of cells within their respective tissues,
thereby sentencing to death any cell that would stray from
its assigned position by either interacting with an inappro-
priately composed ECM or by losing anchorage to its own
ECM. Thus, anoikis partakes greatly in the conﬁguration
and preservation of the proper functional organization of
tissues, thereby ensuring the disposal of cells that assume a
roguish behavior with regards to their precise integrin-ECM
adhesion requirements for survival—whether this occurs
accidentally in the course of normal physiological processes,
such as tissue renewal, or otherwise.
It is undeniable that the regulation of cell survival
and anoikis implicates distinct mechanisms according to
the composition of the ECM, the repertoire of integrins
(and variants) expressed, the degree of cell polarity (i.e.,
cytoskeletal organization) conferred at least in part by spe-
ciﬁc ECM-integrin interactions, the transduction pathways
engaged and/or suppressed through signaling by individual
integrins, the isoforms and/or family members participating
in such pathways, the RTKs expressed which may, or may
not, interfere with their intrusive cross-talk, and the various
regulators/eﬀectorsofapoptosisthatareexpressed.Although
theremaybeameasureofmechanisticcommonalitybetweenJournal of Signal Transduction 13
some cell types, one should always be mindful of the
reality that the integrin-mediated control of cell survival
and anoikis constitutes a complex business that is not
only tissue type- and species context-dependent, but as
well diﬀerentiation state-distinctive. Taking into account
these caveats should allow for an improved focusing on
the precise determinants of cell survival of a given tissue
within the whole of its physiological framework, therefore
facilitating an eventual elucidation of the selective integrin-
mediated underpinnings that are implicated in tissue-
speciﬁc apoptosis/anoikis-linked pathological disorders.
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